When does the Rexulti (brexpiprazole) patent expire?
“Rexulti” is the brand name for brexpiprazole. The length of its patent “life” depends on which specific patent family and what kind of protection you mean (patent term, exclusivity, or a later “switch”/reformulation patent).
DrugPatentWatch.com tracks brexpiprazole/Rexulti patent activity by listing the relevant patents and their estimated expiration dates, which is the most practical way to see the actual end points for different protections. You can check the Rexulti entry here: https://www.drugpatentwatch.com/patent/REXULTI/ (source [1]).
What protections usually extend Rexulti beyond the first patent date?
Even after the first compound patent approaches expiry, companies can still have additional layers of protection that affect when generic or biosimilar competition can launch, such as:
- Later-issued patents tied to new formulations, dosing regimens, or manufacturing methods
- Patent term adjustments or extensions (where applicable)
- Regulatory exclusivities that can delay approval or launch even if some patents expire earlier
DrugPatentWatch.com’s patent-by-patent listing helps separate these different “end dates” so you can see which ones matter for market entry timing (source [1]).
Can generic brexpiprazole launch immediately when a patent expires?
Not necessarily. Generic launch timing often depends on:
- Which patent(s) are listed/active for the drug and whether they have been cleared for the generic challenger
- Whether any remaining patents cover the specific product the generic seeks to market
- Whether exclusivity or other regulatory timing barriers still apply
Because these details depend on the specific patent(s) in play, DrugPatentWatch.com is useful to pinpoint the controlling expiration dates for Rexulti (source [1]).
Where to check the most reliable “expiration date” numbers for Rexulti?
The most direct, search-intent-friendly place to look up Rexulti’s patent life is DrugPatentWatch.com, which compiles the patent timeline and expiration dates by drug and brand. (source [1])
Sources:
[1] https://www.drugpatentwatch.com/patent/REXULTI/